Kalytera’s lead clinical-stage program is focused on developing CBD formulations for both treatment and prevention of acute graft versus host disease (“GVHD”). Kalytera’s lead program in GVHD has recently completed three Phase 2a clinical studies evaluating the safety and efficacy of (1) short term use of CBD in the prevention of acute GVHD, (2) prolonged use of CBD in the prevention of acute GVHD, and (3) prolonged use of CBD in the of treatment steroid-refractory grades 3-4 acute GVHD. Kalytera’s GVHD program was recently acquired pursuant to Kalytera’s acquisition of Talent Biotechs Ltd. (“Talent”), a formerly privately held, Israeli-based developer of CBD therapeutics, as announced on February 16,2017...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.